Miejsce dapagliflozyny w leczeniu niewydolności serca

Źródła

1. McDonagh-TA,-Metra-M,-Adamo-M,-Gardner-RS,-Baumbach-A,-Bohm-M,-et-al.-2021-ESC-Guidelines-for-the-diagnosis-and-treatment-of-acute-and-chronic-heart-failure.-Eur-Heart-J.-2021;42(36):3599-726.
2. Czech-M,-Opolski-G,-Zdrojewski-T,-Dubiel-JS,-Wizner-B,-Bolisęga-D,-et-al.-The-costs-of-heart-failure-in-Poland-from-the-public-payer's-perspective.-Polish-programme-assessing-diagnostic-procedures,-treatment-and-costs-in-patients-with-heart-failure-in-randomly-selected-outpatient-clinics-and-hospitals-at-different-levels-of-care:-POLKARD.-Kardiol-Pol.-2013;71(3):224-32.
3. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-327.
4. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-e1032.
5. Caruso I, Giorgino F. SGLT-2 inhibitors as cardio-renal protective agents. Metabolism. 2022;127:154937.
6. McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019.
7. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-98.
8. Desai AS, Jhund PS, Claggett BL, Vaduganathan M, Miao ZM, Kondo T, et al. Effect of Dapagliflozin on Cause-Specific Mortality in Patients With Heart Failure Across the Spectrum of Ejection Fraction: A Participant-Level Pooled Analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2022;7(12):1227-34.